News

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...
Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...
Estimates for Eli Lilly’s 2025 earnings have declined from $23.06 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same ...
Wealth Enhancement Advisory Services LLC boosted its stake in Eli Lilly by grabbing an extra 15,393 shares, totaling a whopping $125 million-plus investment. Several institutional investors also made ...
Internal documents revealed Takeda and Lilly knew about the bladder cancer risk as early as 1999. After the FDA mandated a bladder cancer warning for Actos in 2011, drug sales dropped by 80% ...